Herantis Pharma has announced an encouraging update from its ongoing Phase Ib trial for lead asset HER-096, which is being developed as a potential disease-modifying treatment for Parkinson's disease (PD). Analysis of the part 1 of the Phase 1b trial provided new pharmacokinetic data for HER-096, confirming ...Den vollständigen Artikel lesen ...
© 2025 Edison Investment Research